DE69922535D1 - Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen - Google Patents

Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen

Info

Publication number
DE69922535D1
DE69922535D1 DE1999622535 DE69922535T DE69922535D1 DE 69922535 D1 DE69922535 D1 DE 69922535D1 DE 1999622535 DE1999622535 DE 1999622535 DE 69922535 T DE69922535 T DE 69922535T DE 69922535 D1 DE69922535 D1 DE 69922535D1
Authority
DE
Germany
Prior art keywords
disease
complex
level
alzheimer
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1999622535
Other languages
English (en)
Other versions
DE69922535T2 (de
Inventor
Jordan L Holtzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69922535D1 publication Critical patent/DE69922535D1/de
Publication of DE69922535T2 publication Critical patent/DE69922535T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69922535T 1998-10-30 1999-10-29 Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen Expired - Lifetime DE69922535T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10639898P 1998-10-30 1998-10-30
US106398P 1998-10-30
US12356499P 1999-03-10 1999-03-10
US123564P 1999-03-10
PCT/US1999/025593 WO2000026251A2 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (2)

Publication Number Publication Date
DE69922535D1 true DE69922535D1 (de) 2005-01-13
DE69922535T2 DE69922535T2 (de) 2005-05-12

Family

ID=26803625

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922535T Expired - Lifetime DE69922535T2 (de) 1998-10-30 1999-10-29 Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen

Country Status (12)

Country Link
US (3) US6972318B1 (de)
EP (1) EP1125135B1 (de)
JP (1) JP4571310B2 (de)
AT (1) ATE284538T1 (de)
AU (1) AU764713B2 (de)
CA (1) CA2348545C (de)
DE (1) DE69922535T2 (de)
IL (2) IL142852A0 (de)
MX (1) MXPA01004317A (de)
NO (1) NO331974B1 (de)
NZ (1) NZ511589A (de)
WO (1) WO2000026251A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011675A (es) * 2000-05-24 2004-07-30 Jordan Loyal Holtzman Agentes y metodos para incrementar los niveles de chaperonin en el cerebro.
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
ATE374784T1 (de) * 2002-12-20 2007-10-15 Hoffmann La Roche Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
JP2012049495A (ja) * 2010-01-29 2012-03-08 Nitto Denko Corp 発光ダイオード装置
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2014012108A1 (en) * 2012-07-13 2014-01-16 Holtzman Jordan L Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
US20180099024A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5707821A (en) 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
JP2001525390A (ja) 1997-12-10 2001-12-11 エヌピーエス ファーマシューティカルズ インコーポレーテッド 抗痙攣薬および中枢神経系活性ビス（フルオロフェニル）アルキルアミド類

Also Published As

Publication number Publication date
WO2000026251A2 (en) 2000-05-11
CA2348545C (en) 2012-08-21
ATE284538T1 (de) 2004-12-15
US20110256569A1 (en) 2011-10-20
NO331974B1 (no) 2012-05-14
IL142852A (en) 2010-05-31
US7927824B2 (en) 2011-04-19
AU764713B2 (en) 2003-08-28
NO20012114L (no) 2001-06-14
AU1810500A (en) 2000-05-22
NO20012114D0 (no) 2001-04-27
EP1125135A2 (de) 2001-08-22
US8211658B2 (en) 2012-07-03
NZ511589A (en) 2005-02-25
JP4571310B2 (ja) 2010-10-27
WO2000026251A3 (en) 2000-08-10
WO2000026251A9 (en) 2001-01-04
MXPA01004317A (es) 2003-06-06
EP1125135B1 (de) 2004-12-08
DE69922535T2 (de) 2005-05-12
US6972318B1 (en) 2005-12-06
JP2002528555A (ja) 2002-09-03
US20060024759A1 (en) 2006-02-02
IL142852A0 (en) 2002-03-10
CA2348545A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
Arena et al. Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer’s disease
Sharp Alpha-1-antitrypsin deficiency
Possin et al. Cross-species translation of the Morris maze for Alzheimer’s disease
Ohtake et al. β-synuclein gene alterations in dementia with Lewy bodies
Weldon et al. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo
Wahlund et al. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients
DE69922535D1 (de) Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen
Greaves et al. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease.
EP2293075A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
El-Mezayen et al. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study
Kobayashi et al. Cerebral cortical calbindin D28K and parvalbumin neurones in Down's syndrome
Martinelli et al. Heightened thrombin generation in individuals with resistance to activated protein C
Pedersen et al. The effect of aquaporin-4 mis-localization on Aβ deposition in mice
Van de Nes et al. Non-tau based neuronal degeneration in Alzheimer's disease—an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex
Gold et al. Reevaluating the role of vascular changes in the differential diagnosis of Alzheimer’s disease and vascular dementia
Kirsch et al. Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy
Braun et al. Value of MRI olfactory bulb evaluation in the assessment of olfactory dysfunction in Bardet–Biedl syndrome
Gurgey et al. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease
Grossman Biomarkers in frontotemporal lobar degeneration
Lanzrein et al. Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease
Laske et al. Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients
Ghomrasseni et al. Morphometric analysis of elastic skin fibres from patients with: cutis laxa, anetoderma, pseudoxanthoma elasticum, and Buschke–Ollendorff and Williams–Beuren syndromes
Wang et al. Will posttranslational modifications of brain proteins provide novel serological markers for dementias?
ATE139803T1 (de) Allelische verbindung des humanen dopamin- (d2)rezeptor-gens in kompulsionsstörungen wie alkoholismus
JP2006300689A (ja) 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition